A — Agilent Technologies, Inc.

Is A overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Agilent Technologies, Inc. (A) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $148.44. The rating moved from Neutral to Overbought on August 6, 2026.

See all overbought Healthcare stocks →

AI analysis

Agilent Technologies, Inc. (A) is positioned to benefit from durable demand for lab instruments, consumables and diagnostics driven by biologics, CRO/CDMO workflows and AI‑enabled lab automation. The business mixes recurring consumables and service revenue with capital equipment sales, supporting cash generation and margin resilience. Near‑term catalysts include expanded adoption of AI‑designed protein workflows and increased diagnostic procedure volumes. Key challenges include cyclical capital spending, competitive pressure from larger peers, FX and regulatory risks. With quiet market conditions and no immediate macro shocks, the stock’s near‑term upside is linked to steady order momentum from biopharma and diagnostics customers and continued execution on margin initiatives.

Key factors

  • Strong exposure to life‑sciences instruments, diagnostics and consumables that benefit from growth in biologics, CRO/CDMO demand and lab automation
  • Recurring consumables and service revenue provide revenue visibility and margin support
  • Clear readthrough from AI-driven protein design and increased demand for DNA/protein synthesis and rapid wet‑lab production
  • Diagnostic and image‑guided procedure tailwinds support equipment and lab services volume
  • Healthy balance‑sheet flexibility historically enables continued R&D, M&A and capital returns (cash generation trend)
  • Limited near‑term macro/market volatility reduces likelihood of large sentiment shocks in quiet trading conditions

Risks

  • Cyclical capital spending by life‑sciences customers; capital equipment orders can be lumpy and sensitive to macro weakness
  • Intense competition from large instrument and lab‑supply peers (e.g., Thermo Fisher, Danaher) that can pressure pricing and share
  • Foreign‑exchange exposure and supply‑chain cost volatility could compress margins
  • Regulatory or reimbursement shifts impacting diagnostic volumes or adoption
  • Payer and healthcare platform margin focus could reduce downstream testing volumes or shift procurement dynamics
  • Dependence on biopharma R&D spending—any slowdown in drug‑development budgets could reduce consumables demand
  • Limited social sentiment and filing data available increases uncertainty about near‑term investor conviction

See today's live rating, score and targets

Members see the live hourly rating for A — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.